Pharmaceutical company Cipla anticipates that its varied operations in the United States will continue to drive its growth, particularly as the U.S. administration is currently restricting funding for global HIV/AIDS initiatives and considering increased tariffs on imported medications to bolster domestic production.
Umang Vohra, Cipla’s Managing Director and Global CEO, remarked that the U.S. government’s stance on the PEPFAR (President’s Emergency Plan for AIDS Relief) program would not adversely affect the company, given that this segment represents a “sub $5 million” business with minimal profit margins. Regarding the potential tariffs on pharmaceuticals, Vohra noted that Cipla has invested approximately $100 million in establishing two inhaler manufacturing facilities in the U.S. and operates a significant oral solid dosage plant. This strategy of diversifying and mitigating risks over the past three years is expected to sustain Cipla’s growth in the U.S. market, he explained during a press briefing following the announcement of the company’s financial performance for the third quarter (Q3) ending December 31, 2024.
The Trump administration is currently reassessing its support for international programs, including PEPFAR, and has temporarily suspended funding. Additionally, the president has indicated that higher tariffs may be applied to pharmaceuticals as part of a strategy to enhance local production capabilities.
The U.S. market is crucial for many Indian pharmaceutical companies and represents Cipla’s second-largest market, following India, contributing approximately 27% of the company’s revenue during the reviewed period.
Cipla reported its highest quarterly revenue to date, reaching ₹7,073 crore in Q3FY25—a 7% increase compared to the same quarter the previous year. The profit after tax (PAT) for the period amounted to ₹1,571 crore, marking a substantial 49% rise year-over-year.
In the same quarter, Cipla’s revenue from the U.S. remained stable at $226 million, supported by strong performances in differentiated products that offset supply challenges with Lanreotide. The company’s One-India business also performed well, generating ₹3,146 crore, a 10% increase from the previous year. Its research and development expenditure totaled ₹360 crore, accounting for 5.1% of sales and reflecting ongoing product development efforts. The company reported a robust net cash position of ₹8,947 crore.
